Key Point: In the STELLAR trial, rosuvastatin established and maintained increased
HDL-C with every dose, while improvements in HDL-C decreased with increasing atorvastatin doses.

In 20-mg and 40-mg-dose comparisons, rosuvastatin therapy resulted in a statistically significant greater increase in HDL-C compared with atorvastatin 20, 40, and 80 mg (P<.002)

Rosuvastatin 10 mg raised HDL-C significantly more than pravastatin 10 mg (P<.002)

Rosuvastatin 20 mg raised HDL-C significantly more than atorvastatin 20, 40,
80 mg, simvastatin 40 mg, and pravastatin 20, 40 mg (P<.002)

Rosuvastatin 40 mg raised HDL-C significantly more than atorvastatin 40,
80 mg, simvastatin 40 mg, and pravastatin 40 mg (P<.002)

Reference

Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin
versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol.
2003;93:152-160.